Publication

Abstract : Present study describes synthesis of a series of Cu(II) metal complexes (C1 - C3) of bidentate Schiff base ligands (L1 - L3) derived from the condensation reaction of 3-amino-2-methyl-4(3H)quinazolinone with 2-chlorobenzaldehyde, 4-bromobenzaldehyde and 2-nitrobenzaldehyde. The structural characterization of synthesized compounds has been analyzed on the basis of FT-IR, UV-Visible, 1H NMR and mass spectroscopy. The orthorhombic structure of the L3 is determined by X-ray crystallographic analysis. In silico analysis of all compounds against various protein targets prove to have better interaction parameters in case of c-MET and VEGFR, thus in accordance with the docking score, the colon cell line (HT-29) was selected for further in vitro analysis and the results revealed that L3, C1, C2 and C3 exhibit important anticancer activity when compared with the standard drug Adriamycin. Further, synthesized compounds have shown excellent activity against Gram-positive (Staphylococcus aureus) and Gram-negative pathogens (Escherichia coli) but exhibited poor activity against fungal strain. Antioxidant activity of the all compounds revealed that the complexes displayed a higher scavenging activity than the corresponding ligands. These studies reveal that the coordination of Cu(II) ion with mixed ligands play a vital role in the enhancement of the biological potential of the complexes.